Dashboard
Manage Tickers

ATNMActinium Pharmaceuticals, Inc.

NYSE actiniumpharma.com


$ 6.99 $ -0.31 (-4.26 %)    

Friday, 05-Jul-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 6.97
$ 7.00
$ 6.98 x 200
$ 0.00 x 0
$ 6.75 - $ 7.05
$ 4.00 - $ 10.24
175,161
na
207.59M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-26-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 10-23-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 06-30-2020 03-31-2020 10-Q
18 05-08-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-15-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 10-31-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
06/17/2024 14:45:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-presents-data-demonstrating-actimab-a-in-combination-with-leading-menin-inhibitors-with-its-arc-actimab-a-in-acute-myeloid-leukemia-at-2024-eha-congress
Actinium Presents Data Demonstrating Actim...
06/17/2024 12:11:03

- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combi...

actinium-presents-oral-presentation-featuring-improved-outcomes-in-tp53-patients-receiving-iomab-b-in-the-phase-3-sierra-trial-at-eha-2024-annual-congress
Actinium Presents Oral Presentation Featur...
06/14/2024 12:41:05

-  Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone ma...

actinium-highlights-data-from-completed-phase-1b-combination-trial-of-actimab-a--clag-m-in-rr-aml-at-2024-society-of-nuclear-medicine--molecular-imaging-annual-meeting
Actinium Highlights Data From Completed Ph...
06/11/2024 12:32:51

actinium-highlights-mutation-data-from-the-phase-3-sierra-trial-of-iomab-b-and-novel-linker-technology-to-support-solid-tumor-antibody-radiation-conjugate-development-at-the-2024-snmmi-annual-meeting
Actinium Highlights Mutation Data From The...
06/10/2024 12:37:13

Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia i...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
05/21/2024 10:52:03

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

reported-earlier-actinium-to-present-improved-survival-outcomes-in-tp53-positive-patients-at-the-eha-2024-and-long-term-efficacy-results-in-older-patients-receiving-an-iomab-b-led-bone-marrow-transplant-in-the-phase-3-sierra-trial
Reported Earlier, Actinium To Present Impr...
05/15/2024 07:11:21

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone mar...

stephens--co-initiates-coverage-on-actinium-pharma-with-overweight-rating-announces-price-target-of-25
Stephens & Co. Initiates Coverage On Actin...
05/14/2024 09:55:15

Stephens & Co. analyst Sudan Loganathan initiates coverage on Actinium Pharma (AMEX:ATNM) with a Overweight rating and a...

actinium-announces-announced-five-abstracts-accepted-for-presentation-at-2024-snmmi-annual-meeting
Actinium Announces Announced Five Abstract...
05/13/2024 12:38:35

-       Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of ...

actinium-announces-kol-webinar-to-highlight-recently-announced-iomab-act-trial-with-leading-fda-approved-commercial-car-t-cell-therapy-being-led-by-the-university-of-texas-southwestern
Actinium Announces KOL Webinar To Highligh...
05/07/2024 12:21:50

Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Inve...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
05/02/2024 17:13:10

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

cantor-fitzgerald-reiterates-overweight-on-actinium-pharma-maintains-21-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/30/2024 14:14:58

Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price ta...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/29/2024 10:10:05

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-highlights-ability-of-iomab-b-to-overcome-high-risk-tp53-mutation-resulting-in-improvement-in-overall-survival-in-patients-with-active-relapsed-refractory-aml-at-the-european-bone-marrow-transplant-annual-meeting
Actinium Highlights Ability Of Iomab-B To ...
04/18/2024 12:11:26

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/01/2024 14:16:58

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

cantor-fitzgerald-reiterates-overweight-on-actinium-pharma-maintains-21-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:24:46

Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price ta...

actinium-announces-iomab-b-phase-3-sierra-trial-results-demonstrating-survival-benefit-in-high-risk-relapsed-or-refractory-acute-myeloid-leukemia-patients-with-tp53-mutations-accepted-for-oral-presentation-at-the-european-bone-marrow-transplant-annual-meeting
Actinium Announces Iomab-B Phase 3 SIERRA ...
04/01/2024 12:09:44

-  The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who othe...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
03/26/2024 16:14:50

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-announces-clinical-trial-to-study-iomab-act-targeted-radiotherapy-conditioning-with-leading-fda-approved-commercial-car-t-cell-therapy
Actinium Announces Clinical Trial to Study...
03/26/2024 11:21:51

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjuga...

maxim-group-maintains-buy-on-actinium-pharma-raises-price-target-to-30
Maxim Group Maintains Buy on Actinium Phar...
03/19/2024 16:59:29

Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)